Journal
JOURNAL OF ALZHEIMERS DISEASE
Volume 89, Issue 1, Pages 193-207Publisher
IOS PRESS
DOI: 10.3233/JAD-220399
Keywords
Alzheimer's disease; assays; cerebrospinal fluid biomarkers; correlation; SOMAscan
Categories
Funding
- National Institutes of Health [R01AG044546, P01AG003991, RF1AG053303, RF1AG058501, U01AG058922]
- Chuck Zuckerberg Initiative
- NIH [P30AG066444, P01AG03991, P01AG026276]
- Hope Center for Neurological Disorders
- Neurogenomics and Informatics Center
- Departments of Neurology and Psychiatry at Washington University School of Medicine
- Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health) [U01AG024904]
- DODADNI (Department of Defense) [W81XWH-12-2-0012]
- National Institute on Aging
- National Institute of Biomedical Imaging and Bioengineering
- AbbVie
- Alzheimer's Association
- Alzheimer's Drug Discovery Foundation
- Araclon Biotech
- BioClinica, Inc.
- Biogen
- BristolMyers Squibb Company
- CereSpir, Inc.
- Cogstate
- Eisai Inc.
- Elan Pharmaceuticals, Inc.
- Eli Lilly and Company
- EuroImmun
- F. Hoffmann-La Roche Ltd.
- Genentech, Inc.
- Fujirebio
- GE Healthcare
- IXICO Ltd.
- Janssen Alzheimer Immunotherapy Research & Development, LLC
- Johnson & Johnson Pharmaceutical Research & Development LLC
- Lumosity
- Lundbeck
- Merck Co., Inc.
- Meso Scale Diagnostics, LLC
- NeuroRx Research
- Neurotrack Technologies
- Novartis Pharmaceuticals Corporation
- Pfizer Inc.
- Piramal Imaging
- Servier
- Takeda Pharmaceutica l Company
- Transition Therapeutics
- Canadian Institutes of Health Research
- Dominantly Inherited Alzheimer Network (DIAN) - National Institute on Aging (NIA) [U19AG032438]
- Alzheimer's Association [SG-20-690363-DIAN]
- German Center for Neurodegenerative Diseases (DZNE)
- Raul Carrea Institute for Neurological Research (FLENI)
- Japan Agency for Medical Research and Development, AMED
- Korea Health Industry Development Institute (KHIDI)
- Spanish Institute of Health Carlos III (ISCIII)
- Canadian Institutes of Health Research (CIHR)
- Canadian Consortium of Neurodegeneration and Aging
- Brain Canada Foundation
- Fonds de Recherche du Quebec -Sante
Ask authors/readers for more resources
This study compared the measurement results of SOMAscan and immunoassay-based methods for five cerebrospinal fluid proteins associated with Alzheimer's disease and neurodegeneration. The results showed that SOMAscan performed as well as immunoassay methods for NfL, Neurogranin, VILIP-1, and sTREM2, but showed weaker correlation for SNAP-25.
Background: The SOMAscan assay has an advantage over immunoassay-based methods because it measures a large number of proteins in a cost-effective manner. However, the performance of this technology compared to the routinely used immunoassay techniques needs to be evaluated. Objective: We performed comparative analyses of SOMAscan and immunoassay-based protein measurements for five cerebrospinal fluid (CSF) proteins associated with Alzheimer's disease (AD) and neurodegeneration: NfL, Neurogranin, sTREM2, VILIP-1, and SNAP-25. Methods: We compared biomarkers measured in ADNI (N = 689), Knight-ADRC (N = 870), DIAN (N = 115), and Barcelona-1 (N = 92) cohorts. Raw protein values were transformed using z-score in order to combine measures from the different studies. sTREM2 and VILIP-1 had more than one analyte in SOMAscan; all available analytes were evaluated. Pearson's correlation coefficients between SOMAscan and immunoassays were calculated. Receiver operating characteristic curve and area under the curve were used to compare prediction accuracy of these biomarkers between the two platforms. Results: Neurogranin, VILIP-1, and NfL showed high correlation between SOMAscan and immunoassay measures (r > 0.9). sTREM2 had a fair correlation (r > 0.6), whereas SNAP-25 showed weak correlation (r = 0.06). Measures in both platforms provided similar predicted performance for all biomarkers except SNAP-25 and one of the sTREM2 analytes. sTREM2 showed higher AUC for SOMAscan based measures. Conclusion: Our data indicate that SOMAscan performs as well as immunoassay approaches for NfL, Neurogranin, VILIP-1, and sTREM2. Our study shows promise for using SOMAscan as an alternative to traditional immunoassay-based measures. Follow-up investigation will be required for SNAP-25 and additional established biomarkers.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available